Results 141 to 150 of about 6,396 (177)
Some of the next articles are maybe not open access.
Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis
Stroke, 2012 Background and Purpose— Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment.
Michael Levy, Rafael Llinas
exaly +2 more sources
Annals of the New York Academy of Sciences, 2010
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio +5 more
openaire +4 more sources
Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio +5 more
openaire +4 more sources
Deferiprone Versus Desferrioxamine in Thalassaemia, and T2* Validation and Utility
Lancet, The, 2003Tim St Pierre
exaly +2 more sources